RAFAEL HOLDINGS, INC. Noncontrolling Interest, Increase from Subsidiary Equity Issuance
RAFAEL HOLDINGS, INC. (RFL) reported Noncontrolling Interest, Increase from Subsidiary Equity Issuance of $12.67 million for the 12-month period ending 2024-07-31, per its 10-K filed 2025-10-29.
Financial Statements › Shareholders' Equity › Noncontrolling Interest Items
us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance · last filed 2025-10-29
- RAFAEL HOLDINGS, INC. noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2024-07-31 was $0.00.
- RAFAEL HOLDINGS, INC. noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2024-04-30 was $12.67M.
- RAFAEL HOLDINGS, INC. noncontrolling interest, increase from subsidiary equity issuance for fiscal 2024 was $12.67M.
| Period end | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 3 month | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 6 month | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 9 month | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 12 month |
|---|---|---|---|---|
| 2024-07-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29 | $12.67M derived: sum of 2 quarters · filed 2025-10-29 | $12.67M 10-K · filed 2025-10-29 | |
| 2024-04-30 | $12.67M 10-Q · filed 2025-06-11 | $12.67M 10-Q · filed 2025-06-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |